- All
- Buy
- Hold
- Sell
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | - | - | - | - | - |
| P/E Ratio | -3.00 | -5.00 | -5.00 | 15.00 | 5.00 |
| EBIT | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Net Profit | - | - | - | - | - |
| Net Profit Adjusted | - | - | - | - | - |
| Pre-Tax Profit | - | - | - | - | - |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | - | - | - | - | - |
| Gross Income | - | - | - | - | - |
| Cash Flow from Investing | - | - | - | - | - |
| Cash Flow from Operations | - | - | - | - | - |
| Cash Flow from Financing | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - |
| Selling, General & Admin. Exp. | - | - | - | - | - |
| Shareholder’s Equity | - | - | - | - | - |
| Total Assets | - | - | - | - | - |
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Unilock Capital Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2022 | Unilock Capital Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2021 | Unilock Capital Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2020 | Unilock Capital Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2019 | Unilock Capital Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2018 | Unilock Capital Corp Registered Shs | - | - | CAD |
*Yield of the Respective Date
Small Pharma, Inc. engages in the development of psychedelic and non-psychedelic medicine. It operates through the Canada and United Kingdom geographical segments. The company was founded on January 23, 2018 and is headquartered in Vancouver, Canada.
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
| Owner | in % |
|---|---|
| Freefloat | 49.00 |
| Biotech Growth Trust Plc (The) | 2.41 |
| OrbiMed Advisors Private Equity | 2.41 |
| AdvisorShares Investments LLC | 0.75 |
| AdvisorShares Psychedelics ETF | 0.75 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLDMraufZaOpvKS3